Clinical Trial

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Name: T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor — clinical trial record (NCT07474168)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor.

Trial Details

NCT Number	NCT07474168
Lead Sponsor	Zhejiang University
Conditions	Tumor
Enrollment	9 participants
Start Date	2025-12-15
Primary Completion	2027-02 (estimated)
Study Completion	2032-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-16